These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33388575)

  • 1. Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities.
    Orner EP; Rodgers MA; Hock K; Tang MS; Taylor R; Gardiner M; Olivo A; Fox A; Prostko J; Cloherty G; Farnsworth CW
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115300. PubMed ID: 33388575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
    Al-Mughales JA; Al-Mughales TJ; Saadah OI
    Front Immunol; 2021; 12():705441. PubMed ID: 34539635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect.
    Maine GN; Lao KM; Krishnan SM; Afolayan-Oloye O; Fatemi S; Kumar S; VanHorn L; Hurand A; Sykes E; Sun Q
    J Clin Virol; 2020 Dec; 133():104663. PubMed ID: 33161369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays.
    Harley K; Gunsolus IL
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33106364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course.
    Higgins V; Fabros A; Wang XY; Bhandari M; Daghfal DJ; Kulasingam V
    Clin Biochem; 2021 Apr; 90():1-7. PubMed ID: 33476578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Back to normal; serological testing for COVID-19 diagnosis unveils missed infections.
    Tsuchida T; Nitahara Y; Suzuki S; Komase Y; Candray K; Kido Y; Nakagama Y; Yamasaki Y; Imamura M; Kawahata K; Kunishima H; Fujitani S; Mineshita M; Matsuda T
    J Med Virol; 2021 Jul; 93(7):4549-4552. PubMed ID: 33739483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.
    Suhandynata RT; Hoffman MA; Kelner MJ; McLawhon RW; Reed SL; Fitzgerald RL
    J Appl Lab Med; 2020 Sep; 5(5):908-920. PubMed ID: 32428207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
    Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y
    J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
    Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
    Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay.
    Batra R; Olivieri LG; Rubin D; Vallari A; Pearce S; Olivo A; Prostko J; Nebbia G; Douthwaite S; Rodgers M; Cloherty G
    J Clin Virol; 2020 Nov; 132():104645. PubMed ID: 32961429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of five widely used serologic assays for antibodies to SARS-CoV-2.
    Stocking C; de Miguel L; Suteu G; Dressel A; Soricelli A; Roskos M; Valor S; Mutschmann C; März W
    Diagn Microbiol Infect Dis; 2022 Feb; 102(2):115587. PubMed ID: 34826767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Longitudinal Evaluation of Six Commercial Immunoassays for the Detection of IgM and IgG Antibodies against SARS CoV-2.
    Nedelcu I; Jipa R; Vasilescu R; Băicuș C; Popescu CI; Manea E; Stoichițoiu LE; Pinte L; Damalan A; Simulescu O; Stoica I; Stoica M; Hristea A
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay.
    Higgins RL; Rawlings SA; Case J; Lee FY; Chan CW; Barrick B; Burger ZC; Yeo KJ; Marrinucci D
    PLoS One; 2021; 16(3):e0247797. PubMed ID: 33661960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological assay for anti-SARS-CoV-2 antibodies improves sensitivity of diagnosis of COVID-19 patients.
    Rostamzadeh D; Mortezagholi S; Alinejad M; Jooya SR; Eskandarian M; Metvaei A; Vafaei S; Aboulghasemi H; Younesi V; Shabani M
    Med Microbiol Immunol; 2021 Dec; 210(5-6):283-289. PubMed ID: 34564742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and performance comparison of three SARS-CoV-2 antibody assays.
    Paiva KJ; Grisson RD; Chan PA; Huard RC; Caliendo AM; Lonks JR; King E; Tang EW; Pytel-Parenteau DL; Nam GH; Yakirevich E; Lu S
    J Med Virol; 2021 Feb; 93(2):916-923. PubMed ID: 32710669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing.
    Conklin SE; Martin K; Manabe YC; Schmidt HA; Miller J; Keruly M; Klock E; Kirby CS; Baker OR; Fernandez RE; Eby YJ; Hardick J; Shaw-Saliba K; Rothman RE; Caturegli PP; Redd AD; Tobian AAR; Bloch EM; Larman HB; Quinn TC; Clarke W; Laeyendecker O
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33208477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
    Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
    J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.